International Psoriasis Council

Advancing Knowledge. Improving Care.

Olusola

Olabisi Ayanlowo

,

MSc, MD

Professor, Consultant Dermatologist
University of Lagos, Nigeria: Lagos University Teaching Hospital
Lagos
,
Nigeria
Councilor Since: January 29, 2024
IPC Councilor
Professor Olusola Ayanlowo is a Professor of Medicine at the College of Medicine, University of Lagos (CMUL) and Honorary Consultant Physician and Dermatologist at the Lagos University Teaching Hospital (LUTH). She graduated from the College of Medicine of the University of Lagos in 1995, did residency training with the West African College of Physicians between 1998 and 2005, and became a fellow in the Faculty of Internal Medicine with a subspecialty in Dermatology. She obtained an MSc in Clinical Dermatology at the St John’s Institute of Dermatology, King’s College, University of London in 2011 and a Doctorate in Medicine at the National Postgraduate Medical College, Nigeria. Professor Ayanlowo is a clinical researcher focused on understanding the genetic basis of cutaneous (skin) and systemic autoimmune disorders with variable phenotypic expressions and profound effects on the quality of life of Nigerians, such as lupus erythematosus, psoriasis, and albinism. She leads the Nigerian Psoriasis Research Team, primarily working to develop the Nigerian Psoriasis Registry. She authored over eighty papers in scientific journals and chapters in textbooks. She is the Editor-in-Chief of the Nigerian Journal of Dermatology, Head of Dermatology and Genitourinary Medicine at LUTH and CMUL, the Director of Postgraduate training in Internal Medicine, and a member of the Medical Education Unit at her university.
Last Updated:
02/01/2024

Areas of Interest

Professor Ayanlowo’s areas of interest are understanding the genetic and phenotypic expressions of Psoriasis in Nigerians and Africans, cardiometabolic presentation of psoriasis, quality of life issues in psoriasis, patient education and engagement, and research management

IPC Committees / Groups

Membership Committee

Languages Spoken

English, French

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026